It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hematopoietic stem and progenitor cells (HSPCs) originate from an endothelial-to-hematopoietic transition (EHT) during embryogenesis. Characterization of early hemogenic endothelial (HE) cells is required to understand what drives hemogenic specification and to accurately define cells capable of undergoing EHT. Using Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq), we define the early subpopulation of pre-HE cells based on both surface markers and transcriptomes. We identify the transcription factor Meis1 as an essential regulator of hemogenic cell specification in the embryo prior to Runx1 expression. Meis1 is expressed at the earliest stages of EHT and distinguishes pre-HE cells primed towards the hemogenic trajectory from the arterial endothelial cells that continue towards a vascular fate. Endothelial-specific deletion of Meis1 impairs the formation of functional Runx1-expressing HE which significantly impedes the emergence of pre-HSPC via EHT. Our findings implicate Meis1 in a critical fate-determining step for establishing EHT potential in endothelial cells.
Hematopoietic stem cell formation via the endothelial-to-hematopoietic transition is initiated by a complex rewiring of the aortic endothelium. Here the authors identify Meis1 as an early driver of hemogenic specification of this arterial endothelium.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 BC Cancer, Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.434706.2) (ISNI:0000 0004 0410 5424); University of British Columbia, Department of Experimental Medicine, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
2 BC Cancer, Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.434706.2) (ISNI:0000 0004 0410 5424); University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
3 BC Cancer, Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.434706.2) (ISNI:0000 0004 0410 5424); University of British Columbia, Interdisciplinary Oncology Program, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
4 BC Cancer, Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.434706.2) (ISNI:0000 0004 0410 5424)
5 BC Cancer, Terry Fox Laboratory, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000)
6 BC Cancer, Terry Fox Laboratory, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000); University of British Columbia, Department of Medical Genetics, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
7 BC Cancer, Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.434706.2) (ISNI:0000 0004 0410 5424); University of British Columbia, Department of Experimental Medicine, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830); University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830); University of British Columbia, Interdisciplinary Oncology Program, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)